Targeting anticancer immunity in melanoma tumor microenvironment: Unleashing the potential of adjuvants, drugs, and phytochemicals
Journal of drug targeting,
Год журнала:
2024,
Номер
32(9), С. 1052 - 1072
Опубликована: Июль 23, 2024
Melanoma
poses
a
challenge
in
oncology
because
of
its
aggressive
nature
and
limited
treatment
modalities.
The
tumour
microenvironment
(TME)
melanoma
contains
unique
properties
such
as
an
immunosuppressive
high-density
environment,
unusual
vasculature,
high
number
stromal
cells.
In
recent
years,
numerous
experiments
have
focused
on
boosting
the
immune
system
to
effectively
remove
malignant
Adjuvants,
consisting
phytochemicals,
toll-like
receptor
(TLR)
agonists,
cytokines,
shown
encouraging
results
triggering
antitumor
immunity
augmenting
therapeutic
effectiveness
anticancer
therapy.
These
adjuvants
can
stimulate
maturation
dendritic
cells
(DCs)
infiltration
cytotoxic
CD8+
T
lymphocytes
(CTLs).
Furthermore,
nanocarriers
help
deliver
immunomodulators
antigens
directly
stroma,
thereby
improving
their
efficacy
against
remodelling
TME
utilising
other
be
combined
with
current
modalities
for
therapy
outcomes.
This
review
article
explores
potential
adjuvants,
drugs,
nanoformulations
enhancing
potency
macrophages,
CTLs,
natural
killer
(NK)
Additionally,
capacity
these
agents
repress
function
components
TME,
subsets
myeloid
will
discussed.
Язык: Английский
Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive Review
Abdulaziz Shebrain,
Omer A. Idris,
Ali Jawad
и другие.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(18), С. 5409 - 5409
Опубликована: Сен. 12, 2024
Over
the
past
several
decades,
advancements
in
treatment
of
Язык: Английский